News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mirna Therapeutics, Inc. Announces Interim Phase 1 Safety Data On Lead Product Candidate MRX34 at American Association for Cancer Research Annual Meeting


4/9/2014 6:29:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Mirna Therapeutics (Mirna), a private, clinical stage biopharmaceutical company focused on the development of microRNA-based oncology therapeutics, today announced interim safety data from a multicenter, open-label Phase 1 clinical trial of MRX34 for the treatment of patients with unresectable primary liver cancer or solid cancers with liver involvement. The data show that MRX34 has a manageable safety profile with only one incident of a dose-limiting toxicity observed to date.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES